J
John H. Kersey
Researcher at University of Minnesota
Publications - 301
Citations - 20968
John H. Kersey is an academic researcher from University of Minnesota. The author has contributed to research in topics: Leukemia & Bone marrow. The author has an hindex of 75, co-authored 301 publications receiving 20531 citations. Previous affiliations of John H. Kersey include Icahn School of Medicine at Mount Sinai & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.
Donald J. Giard,Stuart A. Aaronson,George J. Todaro,Paul Arnstein,John H. Kersey,Harvey Dosik,Wade P. Parks +6 more
Journal ArticleDOI
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.
John E. Wagner,Juliet N. Barker,Todd E. DeFor,K. Scott Baker,Bruce R. Blazar,Cindy R. Eide,Anne I. Goldman,John H. Kersey,William Krivit,Margaret L. MacMillan,Paul J. Orchard,Charles Peters,Daniel J. Weisdorf,Norma K.C. Ramsay,Stella M. Davies +14 more
TL;DR: There is a high probability of survival in recipients of UCB grafts that are disparate in no more than 2 human leukocyte antigens when the grafts contain at least 1.7 x 10(5) CD34(+) cells per kilogram of recipient's body weight, and graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less.
Journal ArticleDOI
Successful Bone-Marrow Transplantation for Infantile Malignant Osteopetrosis
Peter F. Coccia,William Krivit,Jaroslav Cervenka,Carlyle Clawson,John H. Kersey,Taehwan H. Kim,Mark E. Nesbit,Norma K.C. Ramsay,Phyllis I. Warkentin,Steven L. Teitelbaum,Arnold J. Kahn,David M. Brown +11 more
TL;DR: Allogeneic bone-marrow transplantation appears to be the treatment of choice in this fatal disorder and vision, hearing, growth, and development were progressively improving 16 months after transplantation.
Journal ArticleDOI
Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
Scott A. Armstrong,Andrew L. Kung,Andrew L. Kung,Meghann E. Mabon,Lewis B. Silverman,Lewis B. Silverman,Ronald W. Stam,Monique L. den Boer,Rob Pieters,John H. Kersey,Stephen E. Sallan,Stephen E. Sallan,Jonathan A. Fletcher,Todd R. Golub,Todd R. Golub,Todd R. Golub,James D. Griffin,James D. Griffin,Stanley J. Korsmeyer,Stanley J. Korsmeyer +19 more
TL;DR: A mouse model of MLL is developed and bioluminescent imaging is used to determine that PKC412 is active against MLL in vivo and proves cytotoxic to Ba/F3 cells dependent upon activated FLT3 containing either mutation.
Journal Article
A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage.
TL;DR: It is concluded that monoclonal antibody BA-1 may be useful in the study of early stages of human B lymphocyte development and shown weak reactivity with B lymphoblastoid cell lines and failed to react with multiple myeloma and pokeweed mitogen-induced plasma cells.